By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genmab A/S 

Toldbodgade 33

Copenhagen    K-1253  Denmark
Phone: 45-7020-2728 Fax: 45-7020-2729


SEARCH JOBS

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.


YEAR FOUNDED:

February 1999

LEADERSHIP:

CEO and Founder: Jan G. J. van de Winkel, Ph.D.

CFO: David Eatwell

JOBS:
Please click here for Genmab job opportunities.

CLINICAL TRIAL

Please click here for clinical trial information.


PRODUCTS:

All Products

FOLLOW GENMAB:



Key Statistics


Email:
Ownership: Public

Web Site: Genmab A/S
Employees:
Symbol: GEN.CO
 



Industry
Biotechnology


Collaborations

Bionomics Limited  Anti-angiogenesis therapeutic antibody development





Company News
Genmab A/S (GEN.CO) Scores $277 Million DuoBody Technology Tie-Up With Gilead (GILD) 8/11/2016 6:11:09 AM
Genmab A/S (GEN.CO) Announces Financial Results For The First Half Of 2016 And Improves 2016 Financial Guidance 8/10/2016 8:00:38 AM
Genmab A/S (GEN.CO) Announces Phase III Studies Of Ofatumumab In Relapsing Multiple Sclerosis 6/2/2016 8:25:19 AM
Genmab A/S (GEN.CO) Announces Positive Topline Result In Phase III POLLUX Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma 5/19/2016 6:47:18 AM
Genmab A/S (GEN.CO) Announces Daratumumab Data To Be Presented At 2016 ASCO Annual Meeting 4/20/2016 10:44:01 AM
MorphoSys AG Sues Janssen Biotech Inc. (JNJ) And Genmab A/S (GEN.CO) For Patent Infringement 4/4/2016 11:46:30 AM
Genmab A/S (GEN.CO) Release: CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) For Relapsed And Refractory Multiple Myeloma 4/1/2016 12:57:12 PM
Genmab A/S (GEN.CO) Release: Major Shareholder Announcement 2/5/2016 7:31:11 AM
Genmab A/S (GEN.CO) Announces FDA Approval Of DARZALEX (Daratumumab) For Multiple Myeloma And Updates Financial Guidance 11/17/2015 7:57:43 AM
Genmab A/S (GEN.CO) Release: Major Shareholder Announcement 9/30/2015 8:00:11 AM
12345678910...
//-->